Contrasting Asymptomatic and Drug Resistance Gene Prevalence of Plasmodium falciparum in Ghana: Implications on Seasonal Malaria Chemoprevention

Genes (Basel). 2019 Jul 16;10(7):538. doi: 10.3390/genes10070538.

Abstract

Malaria is a significant public health problem in Ghana. Seasonal Malaria Chemoprevention (SMC) using a combination of sulfadoxine-pyrimethamine and amodiaquine has been implemented since 2015 in northern Ghana where malaria transmission is intense and seasonal. In this study, we estimated the prevalence of asymptomatic P. falciparum carriers in three ecological zones of Ghana, and compared the sensitivity and specificity of different molecular methods in identifying asymptomatic infections. Moreover, we examined the frequency of mutations in pfcrt, pfmdr1,pfdhfr, and pfdhps that relate to the ongoing SMC. A total of 535 asymptomatic schoolchildren were screened by microscopy and PCR (18s rRNA and TARE-2) methods. Among all samples, 28.6% were detected as positive by 18S nested PCR, whereas 19.6% were detected by microscopy. A high PCR-based asymptomatic prevalence was observed in the north (51%) compared to in the central (27.8%) and south (16.9%). The prevalence of pfdhfr-N51I/C59R/S108N/pfdhps-A437G quadruple mutant associated with sulfadoxine-pyrimethamine resistance was significantly higher in the north where SMC was implemented. Compared to 18S rRNA, TARE-2 serves as a more sensitive molecular marker for detecting submicroscopic asymptomatic infections in high and low transmission settings. These findings establish a baseline for monitoring P. falciparum prevalence and resistance in response to SMC over time.

Keywords: Plasmodium falciparum; Sulfadoxine-Pyrimethamine; TARE-2; antimalarial drug resistance; asymptomatic infections; pfdhps; phdhfr; quantitative real-time PCR.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimalarials / pharmacology
  • Antimalarials / therapeutic use
  • Asymptomatic Diseases
  • Chemoprevention
  • Drug Resistance*
  • Genes, Protozoan*
  • Ghana / epidemiology
  • Haplotypes
  • Humans
  • Malaria, Falciparum / drug therapy
  • Malaria, Falciparum / epidemiology*
  • Malaria, Falciparum / parasitology*
  • Malaria, Falciparum / prevention & control
  • Mutation
  • Plasmodium falciparum / drug effects*
  • Plasmodium falciparum / genetics*
  • Prevalence
  • Public Health Surveillance
  • RNA, Ribosomal, 18S / genetics
  • Seasons*
  • Sensitivity and Specificity

Substances

  • Antimalarials
  • RNA, Ribosomal, 18S